Biocardia Ownership
| BCDA Stock | USD 2.62 0.02 0.77% |
Biocardia |
Biocardia Stock Ownership Analysis
About 22.0% of the company shares are held by company insiders. The book value of Biocardia was currently reported as 0.61. The company recorded a loss per share of 4.03. Biocardia last dividend was issued on the 6th of June 2019. The entity had 1:15 split on the 30th of May 2024. BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart and Morph deflectable guides and sheaths. Biocardia operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 28 people. For more info on Biocardia please contact Peter Altman at 650 226 0120 or go to https://www.biocardia.com.Besides selling stocks to institutional investors, Biocardia also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Biocardia's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Biocardia's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Biocardia Quarterly Liabilities And Stockholders Equity |
|
Biocardia Insider Trades History
About 22.0% of Biocardia are currently held by insiders. Unlike Biocardia's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Biocardia's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Biocardia's insider trades
Biocardia Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Biocardia is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biocardia backward and forwards among themselves. Biocardia's institutional investor refers to the entity that pools money to purchase Biocardia's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Advisor Group Holdings, Inc. | 2024-12-31 | 61.0 | Sbi Securities Co Ltd | 2024-12-31 | 15.0 | Northern Trust Investments N A | 2024-12-31 | 0.0 | Susquehanna International Group, Llp | 2024-12-31 | 43.8 K | Geode Capital Management, Llc | 2024-12-31 | 31 K | Cm Management, Llc | 2024-12-31 | 25 K | Vanguard Group Inc | 2024-12-31 | 12.9 K | Ubs Group Ag | 2024-12-31 | 4.8 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 4 K | Pingora Partners Llc | 2024-12-31 | 1 K | Jpmorgan Chase & Co | 2024-12-31 | 899 |
Biocardia Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biocardia insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biocardia's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biocardia insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Biocardia Outstanding Bonds
Biocardia issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Biocardia uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Biocardia bonds can be classified according to their maturity, which is the date when Biocardia has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| BIOGEN INC 52 Corp BondUS09062XAD57 | View | |
| BIOGEN INC 405 Corp BondUS09062XAF06 | View | |
| BIOGEN INC Corp BondUS09062XAG88 | View | |
| BIOGEN INC Corp BondUS09062XAH61 | View | |
| BIIB 325 15 FEB 51 Corp BondUS09062XAK90 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Biocardia Corporate Filings
8K | 10th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 7th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 12th of February 2025 Other Reports | ViewVerify | |
| 2nd of December 2024 Other Reports | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biocardia offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biocardia's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocardia Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocardia Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. If investors know Biocardia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocardia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.03) | Revenue Per Share | Quarterly Revenue Growth (0.93) | Return On Assets | Return On Equity |
The market value of Biocardia is measured differently than its book value, which is the value of Biocardia that is recorded on the company's balance sheet. Investors also form their own opinion of Biocardia's value that differs from its market value or its book value, called intrinsic value, which is Biocardia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocardia's market value can be influenced by many factors that don't directly affect Biocardia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biocardia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biocardia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocardia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.